RAC listing today at 11am
check it out
Race Oncology Ltd (RAC) – Rediscovering ‘Bisantrene’ Anti-Cancer Drug
Company Snapshot
Shares on Issue: 52,687,501
Cash at listing: ~$4M
Company Summary
o ~$200M already spent on the development of the drug in the 1980’s
- RAC (formerly Coronado Resources Ltd which acquired 100% of the IP of Update Pharma Inc) will acquire patents for an anti-cancer drug called Bisantrene (the patents were acquired by Update Pharma Inc in 2014 and are valid until 2033)
- Bisantrene was lost in a series of big pharma mergers during the 1990’s and essentially forgotten until its recent discovery by the founders of Update Pharma
- Bisantrene is an anti-cancer drug used in chemotherapy, the highlights being:
o Over 44 clinical studies completed covering more than 2000 patients
o Was shown to possess a tolerable safety profile and useful therapeutic efficacy in several cancers, notably Acute Myeloid Leukaemia (AML)
o Approved for marketing in France for the treatment of AML in 1990
o Phase 2 ready upon the completion of a bridging study
o Holds ‘Orphan Drug Designation’ status
- RAC has established a ‘Freedom to Operate’ on Bisantrene and has filed patents over ‘Use, Formulation and manufacturing’ providing a robust commercial exclusivity
- Potential for larger medium-term sales from a clinical development program in the US, aimed at a general marketing approval for AML and other cancers plus the potential for early revenue under a paid Named Patient Program (NPP) in Europe
How it Works – Not a New Drug
- Bisantrene was first discovered by the pharmaceutical company Lederle (a division of American Cyanamid) in the 1980s
- Bisantrene is an anti-cancer drug similar to the widely used anthracyclines which are the largest selling and frontline chemotherapy drugs worldwide – it has a similar pattern of clinical activity to anthracyclines but lacks the serious side effect of Cardiac Toxicity, providing a greatly improved safety profile and is also less prone to drug-resistance
- It provides for a currently unmet and last line treatment option for patients who have developed anthracycline resistance or reached their dosage threshold
Market Size: AML – Named Patient Program
- AML is a deadly cancer for which there is no effective treatment available on the market
- Bisantrene has been in 5 Phase 2 trials for AML and demonstrated around 50% Complete Response rates in patients that have failed all other therapies and was approved in France for the treatment of AML
- RAC intends to commence its Named Patient Program (NPP) for AML treatment in France and other European markets initially, and then expand into the treatment of other cancers
- The NPP is projected to generate up to $50M in total revenues over 5 years (treatment per patient ~$40k), commencing within 18 months from listing
- Forums
- ASX - Day Trading
- Morning Traders Wednesday 13 th July
Morning Traders Wednesday 13 th July, page-8
-
- There are more pages in this discussion • 240 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity